Pharmacologic Management of High-Risk Neuroblastoma in Children

被引：0
|
作者：
Veena R. Ganeshan
Nina F. Schor
机构：
[1] University of Rochester School of Medicine and Dentistry,Center for Neural Development and Disease, and Department of Pediatrics
[2] University of Rochester Medical Center,Department of Pediatrics
来源：
Pediatric Drugs | 2011年 / 13卷
关键词：
Neuroblastoma; Topotecan; Minimal Residual Disease; Anaplastic Lymphoma Kinase; Isotretinoin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Neuroblastoma is the most common extracranial solid tumor of childhood. It accounts for 15% of pediatric cancer deaths. Children with high-risk disease have a 3-year event-free survival rate of only 20%. Chemotherapy is the mainstay of treatment in children with advanced neuroblastoma.
引用
收藏
页码：245 / 255
页数：10
相关论文
共 50 条
  • [1] Pharmacologic Management of High-Risk Neuroblastoma in Children
    Ganeshan, Veena R.
    Schor, Nina F.
    PEDIATRIC DRUGS, 2011, 13 (04) : 245 - 255
  • [2] Outcome of children with high-risk neuroblastoma
    Fluchel, M
    Hawkins, DS
    Felgenhauer, J
    Douglas, JJ
    Sanders, JE
    Park, JR
    PEDIATRIC RESEARCH, 2003, 53 (04) : 300A - 301A
  • [3] FRACTURE PREVALENCE IN CHILDREN WITH HIGH-RISK NEUROBLASTOMA
    Scruggs, Megan
    Dryden, Abby
    English, Jennifer
    Bowden, Sasigarn
    Shah, Summit
    Stanek, Joseph
    Streby, Keri
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S227 - S228
  • [4] Optimizing the Postoperative Management of Children Undergoing Resection of High-Risk Abdominal Neuroblastoma
    Lee, William G.
    Lascano, Danny
    Palmer, Samiza B.
    Chen, Stephanie Y.
    Mack, Shale J.
    Sudharshan, Rasika
    Han, Jane S.
    Kim, Eugene S.
    AMERICAN SURGEON, 2024, 90 (06) : 1290 - 1297
  • [5] INCIDENCE OF ADRENAL INSUFFICIENCY IN CHILDREN WITH HIGH-RISK NEUROBLASTOMA
    Patterson, Kelli
    Horvath, Kyle
    Metzger, Gregory
    Bourgeois, Tran
    Stanek, Joseph
    Minneci, Peter
    Aldrink, Jennifer
    Streby, Keri
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S228 - S228
  • [6] Vitamin D Status in Children With High-risk Neuroblastoma
    Izurieta-Pacheco, Ana Carolina
    Sangros-Gimenez, Ana
    Martinez-Garcia, Esther
    Perez-Jaume, Sara
    Mora, Jaume
    Gorostegui-Obanos, Maite
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2023, 45 (08) : E953 - E958
  • [7] The efficacy of delayed surgery in children with high-risk neuroblastoma
    Ali, Varan
    Vural, Kesik
    Emin, Senocak Mehmet
    Gulsev, Kale
    Canan, Akyuz
    Munevver, Buyukpamukcu
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (02) : 268 - 271
  • [8] Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma
    Szychot, Elwira
    Peregud-Pogorzelski, Jaroslaw
    Wawrykow, Pawel
    Brodkiewicz, Andrzej
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2016, 70 : 1001 - 1004
  • [9] Value of surgical resection in children with high-risk neuroblastoma
    Englum, Brian R.
    Rialon, Kristy L.
    Speicher, Paul J.
    Gulack, Brian
    Driscoll, Timothy A.
    Kreissman, Susan G.
    Rice, Henry E.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (09) : 1529 - 1535
  • [10] Long Term Outcomes of Children With High-Risk Neuroblastoma
    Sakaguchi, Hirotoshi
    Sajiki, Daichi
    Maemura, Ryo
    Chiba, Kosuke
    Murase, Naruhiko
    Nishikado, Yuichi
    Atsumi, Megumi
    Doisaki, Sayoko
    Yoshida, Nao
    Matsumoto, Kimikazu
    Hama, Asahito
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S106 - S107
12345